Advertisement

Topics

FDA Approves Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease (COPD)

14:11 EST 9 Nov 2018 | Drugs.com

November 09, 2018 -- Today, the U.S. Food and Drug Administration (FDA) approved Yupelri (revefenacin) Inhalation Solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Revefenacin is a long-acting...

Original Article: FDA Approves Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease (COPD)

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease (COPD)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all  lead to the airways in the lungs becoming damaged and thus narrower,  making inhalation and exhalation harder...